公开(公告)号：US10519133B2

公开(公告)日：2019-12-31

申请号：US15750704

申请日：2016-08-03

Applicant: MEDSHINE DISCOVERY INC. ,  HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.

Inventor： Shuhui Chen ,  Zhengxia Chen ,  Meibi Dai ,  Cheng Xie ,  Peng Li ,  Yang Zhang ,  Guibai Liang ,  Qiang Wang ,  Jiangpeng Liao ,  Fei Sun ,  Guoping Hu ,  Jian Li

IPC: C07D401/14 ,  C07D405/14 ,  C07D401/12 ,  C07D413/14 ,  A61P35/00 ,  C07D403/02 ,  C07D403/14 ,  A61K31/416 ,  A61K31/395 ,  C07D235/02 ,  C07D401/02

Abstract: FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

公开(公告)号：US10654868B2

公开(公告)日：2020-05-19

申请号：US16309648

申请日：2017-06-13

Applicant: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.

Inventor： Lun Lu ,  Zhibo Zhang ,  Gang Li ,  Lihong Hu ,  Charles Z. Ding ,  Shuhui Chen

IPC: C07D495/14 ,  C07D498/14 ,  C07D491/147 ,  A61P19/02 ,  A61P3/10 ,  A61P35/00 ,  C07D487/14 ,  A61K31/553 ,  A61K31/551 ,  A61P29/00 ,  A61K31/55

Abstract: Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11078194B2

公开(公告)日：2021-08-03

申请号：US16770196

申请日：2018-12-07

Applicant: HARBIN ZHENBAO PHARMACEUTICAL CO., LTD.

Inventor： Zhengxia Chen ,  Yang Zhang ,  Meibi Dai ,  Hongfei Cheng ,  Suqin Yang ,  Wenju Li ,  Jian Li ,  Shuhui Chen

IPC: C07D405/14 ,  C07D401/14 ,  C07D413/14 ,  C07D401/12 ,  A61P35/00 ,  A61K31/416

Abstract: Disclosed in the present invention are a salt form and a crystal form serving as FGFR and VEGFR inhibitor compounds, a preparation method therefor, and medical uses thereof.

公开(公告)号：US20240109879A1

公开(公告)日：2024-04-04

申请号：US18269901

申请日：2021-12-29

Applicant: Medshine Discovery Inc.

Inventor： Chunli Shen ,  Yuchuan Zhu ,  Jinxin Liu ,  Chengde Wu ,  Jian Li ,  Shuhui Chen

IPC: C07D413/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  C07D417/14

Abstract: Provided are a class of benzimidazole compounds and an application thereof as a 300/CBP inhibitor. Specifically, provided are a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US11702400B2

公开(公告)日：2023-07-18

申请号：US17767104

申请日：2020-10-16

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun Wu ,  Zheming Xiao ,  Chunyan Jiang ,  Jian Li ,  Shuhui Chen

IPC: C07D401/04

CPC classification number: C07D401/04 ,  C07B2200/13

Abstract: Salt types, crystal forms, and preparation methods for benzopyrazole compounds as RHO kinase inhibitors. Specifically, disclosed are hydrochloride and acetate of compounds of formula (I) and crystal forms thereof, as well as application of the salt types and the crystal forms in preparation of RHO inhibitor drugs.

公开(公告)号：US11524941B2

公开(公告)日：2022-12-13

申请号：US17460662

申请日：2021-08-30

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun Wu ,  Lele Zhao ,  Jianjun Sun ,  Zhen Zhan ,  Shuhui Chen

IPC: C07D231/12 ,  C07D401/06 ,  C07D401/04 ,  C07D487/04 ,  C07D403/12 ,  C07D403/06 ,  C07D471/10 ,  C07D401/14

Abstract: Disclosed are a class of pyrazole compounds and applications thereof in the preparation of a medicament for treating related diseases. Specifically, related are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.

公开(公告)号：US11377444B2

公开(公告)日：2022-07-05

申请号：US16760740

申请日：2018-11-02

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Kevin X Chen ,  Zhaoguo Chen ,  Li Zhang ,  Yanxin Yu ,  Kai Zhou ,  Boyu Hu ,  Xiaofei Wang ,  Guoping Hu ,  Jian Li ,  Shuhui Chen

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

公开(公告)号：US11299475B2

公开(公告)日：2022-04-12

申请号：US16967546

申请日：2019-02-02

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Wenyuan Qian ,  Chundao Yang ,  Guanghai Xu ,  Jian Li ,  Shuhui Chen

IPC: C07D401/14 ,  A61P9/12 ,  C07D241/20 ,  C07D401/04 ,  C07D417/14

Abstract: A compound represented by formula (I) or an isomer or a pharmaceutically acceptable salt thereof. The present invention also relates to an application of the same in preparing a drug for treating a disease related to a PGI2 receptor.

公开(公告)号：US20190062338A1

公开(公告)日：2019-02-28

申请号：US15999075

申请日：2017-02-20

Applicant: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ,  Medshine Discovery Inc.

Inventor： Shilan Liu ,  Dahai Wang ,  Guibai Liang ,  Guoping Hu ,  Jian Li ,  Shuhui Chen

IPC: C07D487/14 ,  C07D495/14 ,  C07D519/00

Abstract: Provided are compounds of formula I and formula II or pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The compounds of formula I and formula II or the pharmaceutically acceptable salts of the compounds provide indole 2,3-dioxygenase (IDO) inhibitory activity and are capable of treating IDO-mediated immunosuppressive diseases, such as infectious diseases or cancer.

公开(公告)号：US09856264B2

公开(公告)日：2018-01-02

申请号：US15306965

申请日：2015-04-21

Applicant: MEDSHINE DISCOVERY INC.

Inventor： Lingyun Wu ,  Yuanshan Yao ,  Zhaoguo Chen ,  Shuhui Chen

IPC: A61K31/437 ,  C07D487/04 ,  A61K31/4725 ,  A61K31/55 ,  C07D401/12 ,  C07D471/04

CPC classification number: C07D487/04 ,  A61K31/4725 ,  A61K31/55 ,  C07D401/12 ,  C07D471/04

Abstract: The present invention discloses a class of isoquinolinesulfonyl derivatives as RHO kinase inhibitors, and pharmaceutical compositions thereof, and relates to pharmaceutically acceptable uses thereof. Specifically, the present invention relates to a compound as represented by formula (I), or a pharmaceutically acceptable salt thereof.